



Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.



Letter to the Editor: Obesity hypoventilation syndrome and severe COVID-19



Dear Sir,

The outbreak of coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has been declared a pandemic by the World Health Organization [1]. Obesity is a common cause to aggravate the severity of respiratory diseases [2] which may place obese patients infected by SARS-CoV-2 at risk for pulmonary complications.

We here report the case of a 23-year-old man who attended Wenzhou Central Hospital, Wenzhou, China (on January 21, 2020) after five days of fever, chills, headache, nasal congestion, cough and mild dyspnoea. Other medical comorbidities included metabolic associated fatty liver disease (MAFLD) [3] for five years, obstructive sleep apnoea hypopnea syndrome (OSAHS) for two years, and gout for one year, the latter treated with oral benzbromarone and bicarbonate. At the time of hospital admission, the most relevant clinical findings at baseline included a body mass index (BMI) of 37.3 kg/m² and body temperature of 39.4 °C, white blood cell (WBC) count of 4.8×10^9 /L, neutrophil count of 3.1×10^9 /L, lymphocyte count of 1.2×10^9 /L, platelet count of 217×10^9 /L, C-reactive protein (CRP) of 37.8 mg/L, fasting blood glucose of 4.9 mmol/L, total cholesterol of 4.38 mmol/L, high-density lipoprotein of 0.62 mmol/L, low-density lipoprotein of 1.62 mmol/L, lactic acid dehydrogenase of 271 U/L, uric acid of 602 μmol/L, ferritin of 796 μg/L, lactate of 2.2 mmol/L, and PaO₂/FiO₂ of 205 mm Hg. His chest computed tomography (CT) scan showed bilateral ground-glass opacities (Fig. 1A). On the suspicion of COVID-19, the attending physician ordered salivary testing which was positive for SARS-CoV-2 by real-time RT-PCR assay (RT-PCR).

The patient was immediately transferred to the isolation ward and commenced on nebulized α-interferon (5,000,000 IU) twice per day, oral lopinavir/ritonavir (200 mg/50 mg) twice per day, and oral arbidol (200 mg) thrice per day as recommended by the Chinese COVID-19 Interim Management Guidance (3rd edition) [4]. Because of the increased serum CRP, the patient was suspected to have a bacterial co-infection and empirical treatment with intravenous amoxicillin sodium and clavulanate potassium (1.2 g) thrice per day was commenced. Given his worsening dyspnoea and continued PaO₂/FiO₂ of <300 mm Hg, the patient was subsequently given continuous high-flow oxygen inhalation (6 L/min) via a nasal catheter. Of note, the dyspnoea improved with arterial PaO₂ fluctuating between 94.5–127.5 mm Hg, while the arterial PaCO₂ remained high (46.8–53.9 mm Hg). Several attempts over the next 72 h to improve the PaCO₂ levels by lowering the oxygen therapy flow rate were to no avail. On day nine, the patient had significant improvement in symptoms with PaCO₂ < 40 mm Hg. A follow-up chest

CT scan showed marked improvement in pulmonary infiltration (Fig. 1B). Subsequently, a follow-up CT of the chest on day twenty-one showed evidence of further improvement (Fig. 1C) and he was discharged after two negative oropharyngeal swab tests and one faecal nuclei acid test for the virus by RT-PCR. On follow-up two weeks after discharge, his chest CT showed resolution of the pulmonary infiltrates (Fig. 1D).

This patient was diagnosed with type II acute respiratory failure as the likely result of COVID-19 in the context of other comorbidities including obesity and MAFLD. This is an interesting case in that up to now, only type I acute respiratory failure has been reported in severe COVID-19 patients [5]. Our patient's PaCO₂ levels remained elevated despite multiple attempts to adjust his oxygenation therapy. Fortunately, his hypercapnia improved on day nine which we believe was due to the improvement in pulmonary infiltrates. Previous studies have shown that obesity may cause restrictive lung disease with reduced vital capacity [6]. In our patient, obese hypoventilation syndrome (i.e. BMI ≥ 30 kg/m² and PaCO₂ > 45 mm Hg) was observed, possibly the result of combined severe pulmonary viral and bacterial infection; this can progress to malignant hypoventilation syndrome, a condition typically characterized by a poor prognosis [6]. The current practice guidance for treatment of COVID-19 suggests non-invasive oxygenation management targeting dyspnoeic individuals with PaO₂/FiO₂ levels below 300 mm Hg or primarily in those with type I acute respiratory failure. However, no strategies exist for managing COVID-19 patients with obesity, chronic obstructive pulmonary disease or other diseases that may cause type II acute respiratory failure.

In this patient, worsening hypercapnia might have led to serious sequelae if he had not recovered from his illness. Potential management strategies in deteriorating patients include the use of different oxygenation therapies. In high-flow oxygenation therapy, a moisturized and temperature-controlled airflow provides appropriate respiratory support with moderate positive airway pressure and helps remove mucus plugs to facilitate better oxygen exchange in the lungs and, thereby, increasing PaO₂/FiO₂. However, its effect on improving simultaneous hypercapnia is uncertain. Alternatively, non-invasive ventilation with an oxygen mask might significantly improve both hypoxemia and hypercapnia, in addition to managing the OSAHS. However, non-invasive ventilation is often uncomfortable and is associated with non-compliance and increases the risk of mucus plug accumulation in the lungs. Invasive ventilation may be the most effective strategy for these patient in that all the abovementioned complications can be appropriately managed, especially when the arterial blood gas pH is <7.3 (or correspondingly increased PaCO₂ levels). However, the risk that needs to be balanced is of nosocomial infection through prolonged intubation and transmission risk to healthcare providers of SARS-CoV-2. Overall, in obese patients combined with SARS-CoV-2 infection, especially in slow to recover patients, early invasive ventilation therapy might




Fig. 1. Chest computed tomography of the patient at hospital admission (A) and during the hospital stay on days nine (B), twenty-two (C) and on follow-up two weeks after discharge (D).

be a more appropriate strategy for managing a rapidly deteriorating pulmonary function.

That said, it is reasonable to speculate that obesity with coexisting COVID-19 may predispose patients to the risk of more severe conditions such as obese hypoventilation syndrome. This is more likely in those that are older and with multiple comorbid diseases such as MAFLD, dyslipidaemia and OSAHS, and therefore less likely to have adequate compensatory organ capacity. Future studies are needed to confirm these observations and to better understand the underlying mechanisms linking SARS-CoV-2 infection with the occurrence of type II acute respiratory failure in obese patients.

Declaration of competing interest

The authors have no conflicts of interest related to this article.

References

- [1] World Health Organization. WHO characterizes COVID-19 as a pandemic. <https://www.who.int/emergencies/diseases/novel-coronavirus-2019/events-as-they-happen>; March 11, 2020.
- [2] Gao F, Zheng KI, Wang XB, et al. Obesity is a risk factor for greater COVID-19 severity. *Diabetes Care* 2020.
- [3] Eslam M, Newsome PN, Anstee QM, et al. A new definition for metabolic associated fatty liver disease: an international expert consensus statement. *J Hepatol* 2020. <https://doi.org/10.1016/j.jhep.2020.03.039>.
- [4] China National Health Commission. Diagnosis and treatment of COVID-19 in China. 3rd edition; January 22, 2020. <http://www.nhcgov.cn/zygj/s7653p/202001/f492c9153ea9437bb587ce2ffcbee1fashtml>, Accessed date: 22 January 2020 [In Chinese].
- [5] Guan WJ, Ni ZY, Hu Y, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. *N Engl J Med* 2020. <https://doi.org/10.1056/NEJMoa2002032>.

- [6] Marik PE, Desai HD. Characteristics of patients with the "malignant obesity hypoventilation syndrome" admitted to an ICU. *J Intensive Care Med* 2013;28: 124–30.

Jiao-Feng Huang¹

Department of Liver Research Center, The First Affiliated Hospital of Fujian Medical University, Fuzhou, China

Xiao-Bo Wang¹

Department of Critical Care Medicine, Wenzhou Central Hospital, Wenzhou, China

Kenneth I. Zheng¹

NAFLD Research Center, Department of Hepatology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China

Wen-Yue Liu

Department of Endocrinology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China

Jun-Jie Chen

Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China

Jacob George*

Storr Liver Centre, Westmead Institute for Medical Research, Westmead Hospital and University of Sydney, NSW, Australia

*Correspondence to: J. George, Storr Liver Centre, Westmead Institute for Medical Research, Westmead Hospital and University of Sydney, Westmead 2145, NSW, Australia.
E-mail address: jacob.george@sydney.edu.au

Ming-Hua Zheng**

*NAFLD Research Center, Department of Hepatology, The First Affiliated
Hospital of Wenzhou Medical University, Wenzhou, China
Institute of Hepatology, Wenzhou Medical University, Wenzhou, China
Key Laboratory of Diagnosis and Treatment for The Development of Chronic
Liver Disease in Zhejiang Province, Wenzhou, China*

****Correspondence to:** M.-H. Zheng, NAFLD Research Center, Department of Hepatology, the First Affiliated Hospital of Wenzhou Medical University, No. 2 Fuxue Lane, Wenzhou 325000, China.
E-mail address: zhengmh@wmu.edu.cn

¹Co-first author: Jiao-Feng Huang, Xiao-Bo Wang and Kenneth I. Zheng.